Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccinations

Vaccinations

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

How Reliable Are Official Annual Suicide Numbers in Sri Lanka?

Crisis·2026

Same author

Accelerating <i>Shigella</i> vaccines: from decades of research to global access.

Expert review of vaccines·2026

Same author

Global vaccine development.

Nature medicine·2026

Same author

CEPI Workshop Report: Applying Disease X Vaccine Library and Knowledge Base Approaches to Severe Fever with Thrombocytopenia Syndrome (SFTS).

Vaccines·2026

Same author

A conceptual model for healthcare-seeking research and interventions in cutaneous leishmaniasis.

International journal for equity in health·2026

Same author

Direct, indirect and intangible costs incurred by leptospirosis patients: the magnitude, aspects and methods of assessing the costs - a systematic review and meta-analysis protocol.

BMJ open·2026

Same journal

Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model.

Expert review of vaccines·2026

Same journal

Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis.

Expert review of vaccines·2026

Same journal

Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis.

Expert review of vaccines·2026

Same journal

Whole cell and acellular pertussis vaccines - rethinking the evidence.

Expert review of vaccines·2026

Same journal

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic.

Expert review of vaccines·2026

Same journal

Narrative shielding and prebunking: a synergistic strategy against vaccine hesitancy in pediatrics.

Expert review of vaccines·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 12, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Hepatitis E vaccine landscape update 2025.

Sun Bean Kim¹, Suneth Agampodi², Tarun Saluja¹

¹Clinical, Assessment, Regulatory, Evaluation Unit, International Vaccine Institute, Seoul, South Korea.

Expert Review of Vaccines

|August 4, 2025

Summary

This summary is machine-generated.

Hepatitis E virus (HEV) vaccines are crucial for public health, yet data gaps hinder widespread use. Further research is needed to confirm the safety and efficacy of the HEV 239 vaccine in vulnerable populations.

Keywords:

HEV vaccine landscape Hepatitis E virus clinical manifestations developed HEV vaccines epidemiology

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Experiment Videos

Last Updated: Sep 12, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Area of Science:

Hepatitis E virus (HEV) research
Vaccinology
Public Health

Background:

HEV is a major health concern, especially in resource-limited areas.
Infection poses severe risks to pregnant women and immunocompromised individuals.
Current vaccine availability is limited, with significant data gaps.

Purpose of the Study:

To review the epidemiology, clinical features, and vaccine landscape of HEV.
To assess the current status of HEV vaccine development, including licensed and investigational candidates.
To explore challenges, opportunities, and global policies for HEV control.

Main Methods:

Comprehensive literature review of HEV epidemiology and clinical manifestations.
Analysis of licensed and investigational HEV vaccines, focusing on HEV 239.
Examination of ongoing clinical trials and global health policies.

Main Results:

The HEV 239 vaccine shows high efficacy and cross-genotype protection, approved in China and Pakistan.
Significant data gaps exist regarding HEV 239 safety in pregnant women, children, and immunocompromised individuals.
WHO prequalification is pending, crucial for global accessibility.

Conclusions:

HEV vaccines are vital for disease control but require further investigation for broader application.
Ongoing trials will provide critical data on safety and immunogenicity in diverse populations.
WHO prequalification of HEV 239 is essential for global HEV prevention strategies.